Edition:
United Kingdom

China Regenerative Medicine International Ltd (8158.HK)

8158.HK on Hong Kong Stock

0.15HKD
23 May 2018
Change (% chg)

HK$-0.00 (-0.67%)
Prev Close
HK$0.15
Open
HK$0.15
Day's High
HK$0.15
Day's Low
HK$0.14
Volume
37,750,000
Avg. Vol
23,226,690
52-wk High
HK$0.28
52-wk Low
HK$0.14

Summary

Name Age Since Current Position

Zhanfeng Cui

53 2016 Non-Executive Chairman of the Board

Chunguo Chen

43 2017 Chief Executive Officer, Chief Compliance Officer, Executive Director

Chi Hung Mui

50 2016 Chief Financial Officer

Wing Hang Chan

38 2015 Group Financial Controller

Ray Yip

67 2017 Executive Director, Global Chief Strategy Officer

Chai Fu Cheng

54 2016 Company Secretary

Chengyu Xiong

63 2017 Non-Executive Director, Chief Development Strategy Officer

Bing Woon Chan

69 2014 Independent Non-Executive Director

Jun Fang

55 2017 Non-Executive Independent Director

Chung Fai Pang

45 2012 Independent Non-Executive Director

Yiu Kit Wong

50 2017 Independent Non-Executive Director

Biographies

Name Description

Zhanfeng Cui

Prof. Cui Zhanfeng has been appointed as Non-Executive Chairman of the Board of the Company, effective 07, October 2016. He obtained his Bachelor’s degree of Science from Inner Mongolia Polytechnic University the People’s Republic of China (the “PRC”) in 1982, and a master’s degree of Science in 1984 and doctor’s degree of Philosophy in 1987 from Dalian University of Technology, the PRC. Prof. Cui was a postdoctoral Fellow in the Bioengineering Unit, Strathclyde University, the United Kingdom from 1988 to 1991 and a Lecturer in Edinburgh University from 1991 to 1994. He moved to the Oxford University as a University Lecturer from 1994 to 1999 and was promoted to a Reader in 1999. In 2000, he was elected to the Donald Pollock Chair of Chemical Engineering in the Oxford University at the age of 37. He is also a Professorial Fellow of Hertford College, the Oxford University. He was a visiting professor to Georgia Institute of Technology, the United States of America (“USA”) in 1999 and University of Minnesota, USA in 2004, and to several universities in China. He is a Chartered Scientist, a Chartered Engineer, and a Fellow of the Institution of Chemical Engineers. Prof. Cui was awarded the Doctor of Science (DSc) by the Oxford University in 2009. In 2013, Prof. Cui was elected to a Fellow of the Royal Academy of Engineering (FREng). Prof. Cui was the first Chinese who was elected to a Statutory Chair in the Oxford University. He has a wide range of collaborative activities in the PRC with Chinese Universities and Chinese Academy of Sciences. He was a Chang Jiang Scholar of the Ministry of Education of the PRC and has acted as an adviser to several governmental organisations, including the Overseas Chinese Affair Office of the State Council.

Chunguo Chen

Mr. Chen Chunguo is Chief Executive Officer, Chief Compliance Officer, Executive Director of the Company. He graduated from Dongbei University of Finance and Economics and obtained a Master’s degree. From 1996 to 2012, Mr. Chen served as President of (Dalian Shide Group Co.,Ltd) who was responsible for the overall management this 3000-employee group. Under his management, he established 8 production bases across the country for new construction marterials, all of which were put into operation successfully, and developed over 100 distribution channels, making “Shide Profiles” one of the well-know brands in the PRC. During his appointment, he led the investment in and acquisition of (Lingyun Industrial Corporation Limited*(SSE code: 600480))and (Ningxia Dayuan Chemical Co.,Ltd.*(SSE code: 600146)), and invested in numbers of financial institutions such as (Bank of Dailian Co.,Ltd.), (China Pacific Insurance Co.,Ltd.*), (Sino Life Insurance Co., Ltd.), Sino-Conflux Insurance Company Ltd Bank of Tieling Co.,Ltd.*) and (Invesco Great Wall Fund Management Company Limited*), etc.. Meanwhile, during this period, he also formed (Dalian Shide Petrochemical Co.,Ltd), Shide Group (Hongkong) Holdings Co.,Ltd.), (Dalian Shide Football Club*), (Dalian Shide Investment Co.,Ltd.*) and other dozens of companies. In total, Mr. Chen managed nearly a hundred of parants and subsidiaries and a billon-dollar group during his service in Dalian Shide Group Co.,Ltd.

Chi Hung Mui

Mr. Mui Chi Hung serves as Chief Financial Officer of the Company. He has over 20 years of experience in financing, auditing and accounting. Prior to joining the Company, Mr. Mui held various senior positions in a few listed groups and international accounting firm, including PricewaterhouseCoopers, Lansen Pharmaceutical Holdings Limited (stock code: 503) (“Lansen”), China Smarter Energy Group Holdings Limited (formerly known as “Rising Development Holdings Limited” (stock code: 1004) (“Rising”)) and Legend Strategy International Holdings Group Company Limited (stock code: 1355). He spent 7 years serving as the Financial Controller, Company Secretary and Executive Director in Rising and 5 years serving as the Chief Financial Officer and Company Secretary in Lansen. Mr. Mui obtained his bachelor’s degree in Management majoring in Accounting from the University of Lethbridge in Canada and his master’s degree in Professional Accounting from the Hong Kong Polytechnic University. Mr. Mui is currently a member of AICPA and HKICPA.

Wing Hang Chan

Mr. Chan Wing Hang, CPA, is Group Financial Controller of China Bio-Med Regeneration Technology Limited. Mr. Chan joined the Group in August 2011. He obtained Bachelor Degree in Business Administration (Honors) in Accountancy from City University of Hong Kong and was graduated from University of Hull in January 2012 with Master Degree in Business Management. Mr. Chan is a fellow member of the Association of Chartered Certified Accountants and a member of the Hong Kong Institute of Certified Public Accountants. He is currently the chief financial officer and company secretary of Sijia Group Company Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 1863), in which he is responsible for the overall financial control, company secretarial, compliance and investor relation functions. Mr. Chan had served as the financial controller, qualified accountant and company secretary of China National Materials Company Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 1893). He was the vice financial controller, qualified accountant and company secretary of Western Mining Company Limited (the shares of which are listed on The Shanghai Stock Exchange, stock code: 601168), and the qualified accountant and company secretary of Shinhint Acoustic Link Holdings Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 2728). Mr. Chan has more than 14 years of experience in accounting, finance, compliance, company secretarial, investor relations and initial public offerings.

Ray Yip

Dr. Ray Yip is the Executive Director, Global Chief Strategy Officer of the Company. Dr. Yip is an international public health leader who has made a significant contribution to global health in the areas of nutrition, maternal and child health, HIV/AIDS and tobacco control. Dr. Yip has been working on emergency response to war and famine, long term program and policy development effort in China in recent years. Dr. Yip was the founding director of the Chinese office of U.S. Centers for Disease Control and Prevention (the “CDC”) in 2013, and the China program director of the Bill and Melinda Gates Foundation (the “Foundation”) in 2017. Dr. Yip is known as a specialist for health and medical issues in the People’s Republic of China (“China”).

Chai Fu Cheng

Mr. Cheng Chai Fu is Company Secretary of the Company. Mr. Cheng graduated from Victoria University of Wellington, New Zealand with a bachelor degree of commerce and administration and obtained a Master of Business Administration from Murray State University, Kentucky of the United States of America. He is an associate member of The Hong Kong Institute of Chartered Secretaries with extensive experience in the areas of auditing, accounting and company secretarial work.

Chengyu Xiong

Prof. Dr. Xiong Chengyu is the Non-Executive Director, Chief Development Strategy Officer of the Company. He is currently a professor and a doctoral supervisor of the School of Journalism and Communication of Tsinghua University in China. Professor Xiong has extensive experience in new media studies, media development and journalism. He was a member of each of the Advisory Committee for State Informatisation* and the Advisory Committee for Internet Development and Management, and served as a vice dean of the School of Journalism and Communication of Tsinghua University in China. Professor Xiong currently serves as a member of the University Academic Committee and the chairman of the National Research Center of Cultural Industries in Tsinghua University in China. Professor Xiong was an independent director of each of Hunan TV & Broadcast Intermediary Co., Ltd (Shenzhen Stock Exchange: 000917) and China South Publishing & Media Group Co., Ltd.* (Shanghai Stock Exchange: 601098). He currently serves as an independent director of Jiangsu Broadcasting Cable Information Network Corporation Limited* (Shanghai Stock Exchange: 600959).

Bing Woon Chan

Mr. Chan Bing Woon is Independent Non-Executive Director of China Bio-Med Regeneration Technology Limited. Mr. Chan joined the Group in March 2014. Mr. Chan is a consultant of Yung, Yu, Yuen & Co., Solicitors and Notaries. He has about 39 years experience in the legal profession. Mr. Chan has been involved in numerous public duties including being Advisor of the Joint Mediation Helpline Office. He is also a fellow member of the Hong Kong Institute of Directors, a council member of the Hong Kong Society of Notaries, a member of the Hospital Authority and a general accredited mediator of Hong Kong International Arbitration Centre and the Law of Society of Hong Kong. Mr. Chan was also a past Chairman of the Hong Kong Mediation Council. He is currently an independent non-executive director of Kwoon Chung Bus Holdings Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 306).

Jun Fang

Dr. Fang Jun is Non-Executive Independent Director of the Company. He served as an executive member and the executive vice-chairman of the Cross-straits Medicine Exchange Association of the National Health and Family Planning Commission of the PRC, an executive member and the vice-chairman of China Sexology Association, the publisher and the executive chief editor of the China Sexology Journal and the deputy head of the Sexology Research Center of Peking University Health Science Center. Dr. Fang also assumed various positions such as the executive member and the secretary general of Wu Jieping Medical Foundation. Dr. Fang graduated from Peking University Health Science Center with a master’s degree in Social Medicine and Health Service Management and a doctorate degree in Epidemiology and Health Statistics. Dr. Fang is also an independent non-executive director of HongDa Financial Holding Limited, a company listed on the Stock Exchange (1822.HK).

Chung Fai Pang

Mr. Pang Chung Fai (Benny) is Independent Non-Executive Director of China Bio-Med Regeneration Technology Limited. Mr. Pang joined the Group in September 2012. He is the managing partner of Messrs. Pang & Co., in association with Loeb & Loeb LLP. Between 1997 and 2009, Mr. Pang practiced as a lawyer with several international law firms in Hong Kong and Sydney. He received his Bachelor degree in Laws with honours from Bond University, Australia, in 1996. In 1997, Mr. Pang obtained his Graduate Diploma in Legal Practice and Master Degree in Laws from The College of Law, Sydney and the University of New South Wales, Australia, respectively. He has been admitted as a legal practitioner of the Supreme Court of New South Wales, Australia since 1997 and as a solicitor of the High Court of Hong Kong since 2009. Mr. Pang is a member of both the Law Society of New South Wales, Australia and the Law Society of Hong Kong. He is currently an independent non-executive director of Yuanda China Holdings Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 2789), and Goldenmars Technology Holdings Limited(the shares of which are listed on the Growth Enterprise Market of the Stock Exchange, stock code: 8036).

Yiu Kit Wong

Mr. Wong Yiu Kit Ernest is an Independent Non-Executive Director of the Company. He has over 25 years of experience in venture capital, corporate finance, business development and general management. Mr. Wong has served as the president and group chief financial officer of KVB Kunlun Holdings Limited (“KVB”) since November 2011 and as the chief financial officer and the company secretary of KVB’s group company, KVB Kunlun Financial Group Limited, the shares of which are listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) (HKEx stock code: 8077) since October 2014. Mr. Wong has also served as an independent non-executive director of Renheng Enterprise Holdings Limited (HKEx stock code: 3628) since October 2011, HongDa Financial Holding Limited (HKEx stock code: 1822) since July 2014, Legend Strategy International Holdings Group Company Limited (HKEx stock code: 1355) since November 2016 and Progressive Path Group Holdings Limited (HKEx stock code: 1581) since November 2016. Mr. Wong also served several positions at Adamas Finance Asia Limited (LSE stock code: ADAM), including its executive director from May 2008 to February 2014, its chief financial officer from May 2008 to October 2011 and its non-executive director since February 2014. Mr. Wong obtained a bachelor’s degree in business administration from The University of Hong Kong in 1991, a master’s degree of science in investment management from The Hong Kong University of Science and Technology in 1998 and a master’s degree of science in electronic engineering from The Chinese University of Hong Kong in 2008.